SELLAS Life Sciences Group, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $9.3M | $2.5M | $0 | $0 |
| Cost of Revenue | — | — | — | — | $1.4M | $520.0K | $0 | $0 |
| Gross Profit | — | — | — | — | $7.9M | $2.0M | $0 | $0 |
| Gross Margin | — | — | — | — | 84.9% | 79.1% | — | — |
| Operating Expenses | ||||||||
| Research & Development | $8.8M | $6.1M | $11.4M | — | — | — | $14.6M | $3.9M |
| SG&A Expense | $12.8M | $15.1M | $4.6M | — | — | — | $6.6M | $8.6M |
| Operating Income | $-29.0M | $-23.0M | $-16.0M | $-34.2M | $-43.9M | $-28.5M | $-21.2M | $-12.5M |
| Operating Margin | — | — | — | — | -471.1% | -1,145.5% | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-29.0M | $-23.5M | $-17.7M | $-38.6M | $-28.3M | $-70.3M | $-34.4M | $-3.4M |
| Income Tax Expense | $-1.4M | $253.0K | $1.0K | $365.0K | $0 | $1.1M | $-1.1M | — |
| Net Income | $-27.7M | $-23.8M | $-17.7M | $-63.9M | $-36.6M | $-76.7M | $-35.0M | $-11.5M |
| Net Margin | — | — | — | — | -392.8% | -3,083.2% | — | — |
| EPS (Basic) | $-78.86 | $-5.22 | $-9.33 | $-4.12 | $-3.07 | $-0.43 | $-0.28 | $-0.16 |
| EPS (Diluted) | $-78.86 | $-5.22 | $-9.33 | $-4.12 | $-3.07 | $-0.43 | $-0.28 | $-0.16 |
| Shares Outstanding (Basic) | 881.1K | 11.5M | 2.5M | 16.2M | 218.9M | 218.9M | 165.8M | 94.3M |
| Shares Outstanding (Diluted) | 881.1K | 11.5M | 2.5M | 16.2M | 218.9M | 218.9M | 165.8M | 94.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |